Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1

Aleksandr I Ilin; Murat E Kulmanov; Ilya S Korotetskiy; Gulshara K Akhmetova; Marina V Lankina; Sergey V Shvidko; Oleg N Reva

doi:10.1128/genomeA.01272-15

Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1

Genome Announc. 2015 Nov 5;3(6):e01272-15. doi: 10.1128/genomeA.01272-15.

Authors

Aleksandr I Ilin¹, Murat E Kulmanov¹, Ilya S Korotetskiy², Gulshara K Akhmetova¹, Marina V Lankina¹, Sergey V Shvidko¹, Oleg N Reva³

Affiliations

¹ Scientific Center for Anti-Infectious Drugs (SCAID), Almaty, Kazakhstan.
² Scientific Center for Anti-Infectious Drugs (SCAID), Almaty, Kazakhstan laeda81@gmail.com.
³ Center of Bioinformatics and Computational Biology (CBCB), Department of Biochemistry, University of Pretoria, Pretoria, South Africa.

Abstract

Complete genome sequence of the multidrug-resistant clinical isolate Mycobacterium tuberculosis SCAID 187.0 containing several drug-resistance mutations is presented. This strain is used in experiments to study genomic and population changes leading to reversion of susceptibility to the 1st line anti-tuberculosis (TB) drugs under the influence of a new medicinal drug FS-1.